Questions About the Oxford-AstraZeneca COVID-19 Vaccine (AZD1222) Data

By Nana Dadzie Ghansah

Courtesy of BioWorld

day or so ago, the Oxford-AstraZeneca group reported findings from an interim analysis of their AZD1222 COVID-19 vaccine (aka ChAdOx1 nCoV-19 vaccine) Phase II/III (COV002) and Phase III (COV003) trials.

Disparities in the findings they reported raise some questions.